Used in cancer immunotherapy research to block the B7-H4 immune checkpoint protein, which helps tumors evade immune detection. By inhibiting B7-H4, this reference antibody enhances T-cell activation and anti-tumor immune responses. It serves as a tool for developing therapeutic antibodies and diagnostic assays targeting B7-H4-expressing cancers such as breast, ovarian, and lung carcinomas. Widely utilized in preclinical studies to evaluate target engagement, efficacy, and safety of novel immunotherapies. Also supports biomarker discovery and validation in tumor microenvironment studies.